FINWIRES · TerminalLIVE
FINWIRES

午间要闻:GE Vernova股价因强劲的第一季度盈利和业绩指引而上涨;Vertiv第一季度每股收益和营收均超预期,上调业绩指引,股价下跌

By

-- 周三上午晚些时候,受伊朗袭击霍尔木兹海峡船只以及美国总统特朗普延长交战国停火协议的报道提振,美国三大股指均上涨。 公司方面,通用电气Vernova(GEV)周三公布第一季度财报,每股收益为17.44美元,高于去年同期的0.91美元。第一季度总营收为93.4亿美元,高于去年同期的80.3亿美元,也高于FactSet分析师一致预期的92.5亿美元。该公司预计2026年营收将在445亿美元至455亿美元之间,高于此前预期的440亿美元至450亿美元,也高于FactSet一致预期的446.6亿美元。GE Vernova股价在午盘前后上涨了12.4%。 Vertiv (VRT) 周三公布了第一季度调整后每股收益为 1.17 美元,高于去年同期的 0.64 美元,也高于 FactSet 预测的 1.00 美元。第一季度营收为 26.5 亿美元,高于去年同期的 20.4 亿美元,也高于 FactSet 预测的 26.4 亿美元。该公司预计第二季度调整后每股收益为 1.37 美元至 1.43 美元,营收为 32.5 亿美元至 34.5 亿美元。FactSet 调查的分析师预期分别为 14.3 亿美元和 34 亿美元。Vertiv 预计 2026 财年全年调整后每股收益为 6.30 美元至 6.40 美元,高于此前预测的 5.97 美元至 6.07 美元,也高于 FactSet 预测的 6.12 美元。 Vertiv预计全年营收为135亿美元至140亿美元,高于此前预期的132.5亿美元至137.5亿美元,也高于FactSet的普遍预期136.3亿美元。Vertiv股价下跌2.6%。 据路透社周三援引知情人士报道,德国默克集团(Merck KGaA)和日本小野药品工业株式会社(Ono Pharmaceutical)已对Inhibrx Biosciences(INBX)的实验性抗癌药物表示出兴趣,该药物估值可能超过80亿美元。默克股价下跌0.2%,而Inhibrx股价上涨31.9%。 波音公司(Boeing BA)周三公布第一季度核心亏损为每股0.20美元,较去年同期的每股亏损0.49美元有所收窄,也高于FactSet普遍预期的每股亏损0.68美元。波音公司第一季度营收为222.2亿美元,高于去年同期的195亿美元,也高于FactSet此前预测的218.5亿美元。该季度现金流出为14.5亿美元,较去年同期的22.9亿美元有所收窄。公司表示,第一季度飞机交付量增长10%,达到143架。波音股价上涨5.4%。 据彭博社周三报道,Alphabet(GOOG,GOOGL)旗下的谷歌云将推出一项7.5亿美元的基金,旨在帮助埃森哲(ACN)、麦肯锡和德勤等咨询公司引导其客户使用智能体人工智能软件。彭博社援引了一份电子邮件声明和对一位公司高管的采访报道了这一消息。Alphabet的C类股和A类股分别上涨1.5%和1.6%。埃森哲股价下跌1.9%。 菲利普莫里斯国际公司(PM)周三公布了第一季度调整后每股收益为1.96美元,高于去年同期的1.69美元,也高于FactSet预期的1.83美元。第一季度净营收为101.5亿美元,高于去年同期的93亿美元,也高于FactSet预期的99.1亿美元。菲利普莫里斯预计第二季度调整后每股收益为2.02美元至2.07美元,低于FactSet预期的2.12美元。该公司预计2026财年全年调整后每股收益为8.36美元至8.51美元,高于FactSet预期的8.38美元。菲利普莫里斯股价上涨7%。 波士顿科学公司(BSX)周三公布了第一季度调整后每股收益为0.80美元,高于去年同期的0.75美元,也高于FactSet预期的0.79美元。第一季度净销售额为52亿美元,高于去年同期的46.6亿美元,也高于FactSet预测的51.7亿美元。波士顿科学公司预计第二季度调整后每股收益为0.82美元至0.84美元,净销售额增长5.5%至7.5%。FactSet调查的分析师预计调整后每股收益为0.86美元。该公司预计2026财年全年调整后每股收益为3.34美元至3.41美元,低于此前预测的3.43美元至3.49美元,也低于FactSet预测的3.45美元。全年净销售额预计增长约7.0%至8.5%,低于此前10.5%至11.5%的预期。该公司股价上涨8.4%。 AT&T (T) 周三公布了第一季度财报,稀释后每股收益为 0.54 美元,低于去年同期的 0.61 美元,也低于 FactSet 预期的 0.55 美元。第一季度营业收入为 315.1 亿美元,高于去年同期的 306.3 亿美元,也高于 FactSet 预期的 312.5 亿美元。AT&T 股价下跌 1.8%。

Price: $1119.35, Change: $+128.05, Percent Change: +12.92%

Related Articles

Treasury

Scotiabank Previews This Week's February and Preliminary March GDP for Canada

Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.

$$CXY
Australia

Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing

Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%

$VICR
Australia

BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%

$BMRN$FOLD